Matches in SemOpenAlex for { <https://semopenalex.org/work/W3008208406> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W3008208406 abstract "394 Background: It is essential to study real-world evidence of novel molecular diagnostic tests to measure their impact on clinical decision-making and health outcomes. Studying test utilization within the Department of Veterans Affairs (VA) informs about clinical validity in a racially diverse population. This study analyzed the impact of DNA promoter methylation (ConfirmDx), on the diagnostic workup of Veterans. Methods: The VA Corporate Data Warehouse (CDW) was used to identify all incident prostate biopsies and cancers from 1/2014-10/2019. We captured patient clinical characteristics, including number and date of biopsies, date of cancer diagnosis, dates and values of PSA tests, comorbidities, demographics, whether the patient underwent DNA promoter methylation testing, and the results of that test. Results: Each year an average of 25,299 biopsies are conducted in the VA. Between 2014 and 2019, 151,794 biopsies were performed. 98,155 (70%) Veterans underwent first-time biopsies and 54,447 (55%) were positive for carcinoma. 8,062 (8.2%) underwent multiple biopsies, among whom 3,589 (44%) were subsequently diagnosed with cancer. 34 Veterans underwent 5 or more biopsies before being diagnosed. 33,878 (35%) did not undergo another biopsy in the study period. 328 (0.3%) of the 98,155 Veterans underwent the DNA promoter methylation test. 55 (17%) of these Veterans were eligible for Medicare coverage of the test. Of the 328 tested for DNA methylation, 217 (66%) were minorities. 132/328 (40%) tested positive for carcinoma and 168/328 (51%) were negative. Conclusions: Most Veterans referred for prostate biopsy have detectable cancer, and a large number are minorities with potential increased prostate cancer risk. DNA promoter methylation may improve care by reducing the need for multiple biopsies, limiting exposure to infection, and reducing time to diagnosis and treatment." @default.
- W3008208406 created "2020-03-06" @default.
- W3008208406 creator A5030877878 @default.
- W3008208406 creator A5037435182 @default.
- W3008208406 creator A5048214696 @default.
- W3008208406 creator A5088127847 @default.
- W3008208406 creator A5088134059 @default.
- W3008208406 date "2020-02-20" @default.
- W3008208406 modified "2023-09-23" @default.
- W3008208406 title "The use of DNA promoter methylation testing for prostate cancer diagnosis in the Department of Veterans Affairs." @default.
- W3008208406 doi "https://doi.org/10.1200/jco.2020.38.6_suppl.394" @default.
- W3008208406 hasPublicationYear "2020" @default.
- W3008208406 type Work @default.
- W3008208406 sameAs 3008208406 @default.
- W3008208406 citedByCount "0" @default.
- W3008208406 crossrefType "journal-article" @default.
- W3008208406 hasAuthorship W3008208406A5030877878 @default.
- W3008208406 hasAuthorship W3008208406A5037435182 @default.
- W3008208406 hasAuthorship W3008208406A5048214696 @default.
- W3008208406 hasAuthorship W3008208406A5088127847 @default.
- W3008208406 hasAuthorship W3008208406A5088134059 @default.
- W3008208406 hasConcept C104317684 @default.
- W3008208406 hasConcept C121608353 @default.
- W3008208406 hasConcept C126322002 @default.
- W3008208406 hasConcept C143998085 @default.
- W3008208406 hasConcept C150194340 @default.
- W3008208406 hasConcept C185592680 @default.
- W3008208406 hasConcept C190727270 @default.
- W3008208406 hasConcept C2775934546 @default.
- W3008208406 hasConcept C2775969662 @default.
- W3008208406 hasConcept C2780192828 @default.
- W3008208406 hasConcept C2908647359 @default.
- W3008208406 hasConcept C55493867 @default.
- W3008208406 hasConcept C71924100 @default.
- W3008208406 hasConcept C99454951 @default.
- W3008208406 hasConceptScore W3008208406C104317684 @default.
- W3008208406 hasConceptScore W3008208406C121608353 @default.
- W3008208406 hasConceptScore W3008208406C126322002 @default.
- W3008208406 hasConceptScore W3008208406C143998085 @default.
- W3008208406 hasConceptScore W3008208406C150194340 @default.
- W3008208406 hasConceptScore W3008208406C185592680 @default.
- W3008208406 hasConceptScore W3008208406C190727270 @default.
- W3008208406 hasConceptScore W3008208406C2775934546 @default.
- W3008208406 hasConceptScore W3008208406C2775969662 @default.
- W3008208406 hasConceptScore W3008208406C2780192828 @default.
- W3008208406 hasConceptScore W3008208406C2908647359 @default.
- W3008208406 hasConceptScore W3008208406C55493867 @default.
- W3008208406 hasConceptScore W3008208406C71924100 @default.
- W3008208406 hasConceptScore W3008208406C99454951 @default.
- W3008208406 hasLocation W30082084061 @default.
- W3008208406 hasOpenAccess W3008208406 @default.
- W3008208406 hasPrimaryLocation W30082084061 @default.
- W3008208406 hasRelatedWork W10662955 @default.
- W3008208406 hasRelatedWork W16537264 @default.
- W3008208406 hasRelatedWork W17183283 @default.
- W3008208406 hasRelatedWork W17821756 @default.
- W3008208406 hasRelatedWork W425306 @default.
- W3008208406 hasRelatedWork W5652776 @default.
- W3008208406 hasRelatedWork W5850796 @default.
- W3008208406 hasRelatedWork W6858922 @default.
- W3008208406 hasRelatedWork W6947022 @default.
- W3008208406 hasRelatedWork W9861191 @default.
- W3008208406 isParatext "false" @default.
- W3008208406 isRetracted "false" @default.
- W3008208406 magId "3008208406" @default.
- W3008208406 workType "article" @default.